The present invention relates to a method for simulation of quality impact of transportation on a liquid, and a two-dimensional shaker adapted to perform said method.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
H01J 49/00 - Particle spectrometers or separator tubes
H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
5.
FILLING APPARATUS AND METHOD FOR FILLING A REUSABLE RESERVOIR OF A MEDICAL DISPENSING DEVICE
The present invention relates to a filling apparatus for filling a reusable reservoir of a medical dispensing device, the filling apparatus comprises a receiving portion for a reusable reservoir, a supply container for containing a liquid medication, a first connection port for fluidly connecting an inner volume of the reusable reservoir with the supply container, and a sterilization device that is configured for sterilizing the inner volume of the reusable reservoir. In order to provide an improved sterilization, the filling apparatus further comprises a discharging device for discharging deposit from the inner volume of the inner volume, wherein the sterilization device comprises a radiation source for providing a radiation for sterilizing the reusable reservoir. The reusable reservoir is housed in a radiation chamber.
An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with IMiDs. The combination therapy may further comprise a glucocorticosteroid.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
8.
COMBINATION THERAPY OF A GPRC5D TCB AND PROTEASOME INHIBITORS
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.
Computer-implemented methods of providing a disease diagnosis or prognosis for a patient are described. These comprise generating individual networks, each individual network comprising a plurality of nodes and edges between pairs of the nodes, wherein each node is indicative of a biological factor in biological data for an individual, and each edge is indicative of a relationship between a pair of biological factors corresponding to the nodes that the edge connects for the respective individual; determining the value of one or more similarity metrics between one or more individual networks generated for the patient and one or more individual networks generated for other individuals in the plurality of individuals; and predicting a diagnosis or prognosis for the patient using a machine learning model that takes as input the values of one or more similarity metrics.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Herein is reported a method for classifying cells in a cell mixture, wherein the mixture comprises T-cells and B-cells, comprising the steps of first applying at least labelled antibodies binding to F-actin, MHCII and CD3 to the cell mixture to obtained a labelled cell mixture, wherein the antibodies are each labelled with a dye, wherein the dyes have different (non-overlapping) emission wavelengths, second acquiring at least one image of the cell mixture, and third classifying the cells in the cell mixture to be an isolated cell if the cell is a single cell, is F-Actin positive and is MHCII positive and CD3 negative, or is MHCII negative and CD3 positive, or to be a doublet or multiplet of cells if the cell is an aggregate of two or three cells, is F- Actin positive, MHCII positive and CD3 positive.
A diagnostic device configured to count a number of swallows of a user, the device comprising: at least one processor; a user interface; one or more sensors associated with the device; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt, via the user interface, the user to provide a user input via the one or more sensors associated with the device each time the user is at a predetermined point during a swallowing action; receive a plurality of inputs via the one or more sensors, each user input corresponding to a respective time at which the user is at a predetermined point during the swallowing action; generate, in response to receiving each user input, a timestamp associated with the respective user input; apply a counting model to data comprising the plurality of generated timestamps, wherein the counting model is configured to calculate a number of swallows of a user by counting the total number of timestamps in the data comprising the plurality of generated timestamps; and outputting the calculated number of swallows.
Methods of sequencing by expansion and related improvements to the sequencing of surrogate polymers in a nanopore are described. The surrogate polymer is formed from a template nucleic acid molecule. A surrogate polymer includes multiple units. Each unit includes a reporter code portion. The reporter codes correspond to the different nucleotides. surrogate polymers may get stuck in the nanopore. Embodiments described herein address these stuck surrogate polymers. In order to allow for multiple reads on the surrogate polymer, a processive consensus technique can be applied. The surrogate polymer may be moved a few units forward and then fewer units backward so that some of the same reporter codes are identified again. This method allows for multiple reads of the same reporter codes. The surrogate polymer eventually passes through the nanopore in the forward direction. Periodically, higher clearing voltages may be applied to clear any stuck surrogate polymer in the nanopore.
Respiration rate measurement A diagnostic device configured to measure a respiration rate of a user, the device comprising: at least one processor; a user interface; one or more sensors associated with the device; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt, via the user interface, the user to provide a user input via the one or more sensors associated with the device each time the user is at a predetermined point during an inhalation cycle; receive a plurality of user inputs via the one or more sensors, each user input corresponding to a respective time at which the user is at a predetermined point during an inhalation cycle; generate, in response to receiving each user input, a timestamp associated with the respective user input; apply a respiration rate model to data comprising the plurality of generated time stamps, wherein the respiration rate model calculates a respiration rate of the user based on the generated time stamps; and output the calculated respiration rate.
A diagnostic device configured to assess respiratory function, lung capacity, abdominal strength and/or thoracic strength or impairments of a subject, the diagnostic device comprising: a processor; a microphone; and a memory storing computer- readable instructions that, when executed by the processor, cause the diagnostic device to: prompt the subject to perform a diagnostic task of making a long "aaah" sound for a predetermined duration; receive audio data associated with the diagnostic task via the microphone; extract, from the audio data, digital biomarker data; and apply an analytical model to the extracted digital biomarker data, the analytical model configured to generate an output indicative of the respiratory function, lung capacity, abdominal strength and/or thoracic strength or impairments of the subject
G10L 25/03 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters
G10L 25/78 - Detection of presence or absence of voice signals
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61B 5/22 - Ergometry; Measuring muscular strength or the force of a muscular blow
A diagnostic device configured to assess the speech function of a subject, the diagnostic device comprising: at least one processor; a microphone; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt the subject to perform a diagnostic task of speaking aloud; receive, via the microphone, audio data associated with the diagnostic task; extract, from the audio data, digital biomarker data associated with the speech function of the subject; and applying a speech function assessment model to the digital biomarker data, the speech function assessment model configured to generate an output indicative of the speech function of the subject.
G10L 25/03 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the type of extracted parameters
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
G10L 25/78 - Detection of presence or absence of voice signals
17.
IMPROVED PROTEASE-ACTIVATABLE T CELL BISPECIFIC ANTIBODIES
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A diagnostic device (110) for monitoring at least one body tissue (134) of a patient is disclosed. The diagnostic device (110) comprises: a. at least one bracelet (112) configured to be strapped around a body part (132) of the patient; b. at least one electromechanical actuator (114) configured for actively varying a circumference of the bracelet (112); c. at least one measurement unit (126) configured for determining at least one item of information on an electrical power applied to the electromechanical actuator (114) and at least one item of circumference information on the circumference of the bracelet (112); and d. at least one evaluation unit (128) configured for determining at least one item of information on a status of the body tissue (134) from the item of information on the electrical power applied to the electromechanical actuator (114) and the item of circumference information, wherein the evaluation unit (128) is configured for determining a point of contact at which the circumference of the bracelet (112) corresponds to the circumference of the body part. Further, a method of monitoring at least one body tissue (134) of a patient is disclosed.
A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
The present invention generally relates to novel protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site, wherein the linker has a length of 20 to 45 amino acids, wherein the masking moiety is covalently attached to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide thereby reversibly concealing the IL-2 polypeptide, wherein the masking moiety comprises a second protease cleavage site, wherein the masking moiety does not conceal the IL-2 polypeptide upon cleavage at the first and/or the second protease cleavage site. The present invention also relates to polynucleotides encoding such protease-activatable interleukin-2 (IL-2) polypeptides and immunconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates of the invention, and to methods of using these protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates in the treatment of disease.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
20.
SUPPLY CHAIN OPTIMIZATION WITH REINFORCEMENT LEARNING
The present invention relates to systems and methods to optimize a supply chain. Various embodiments of the present invention relate to systems and methods to optimize a multi-distribution-level supply chain and, more specifically but not limited, to systems and methods to optimize a multi-distribution-level supply chain via a machine-learning model based on reinforcement learning.
The invention provides compounds having the general formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein A, L, n, and R1to R3 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines
C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups
This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.
Herein is reported a method for separating full and empty recombinant adeno- associated virus particles using an anion exchange chromatography step, wherein the method comprises a sequence of a applying a solution comprising empty and/or full rAAV particles to an anion exchange chromatography material inside a chromatography column, a first isocratic step, a first linear gradient, a second isocratic step and a second linear gradient, wherein the empty recombinant adeno- associated virus particles are eluted during the first linear gradient and the full recombinant adeno-associated virus particles are eluted during the second linear gradient. In certain embodiments, the solution applied in the first isocratic step comprises about (65) mM of the buffer substance, about (10) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the solution applied in the second isocratic step comprises about (65) mM of the buffer substance, about (90) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the buffer substance is N-(1,1-Dimethyl- (2)-hydroxyethyl)-(3)-amino-2-hydroxypropane sulfonic acid, the elution salt is tetramethyl ammonium chloride, and the salt is magnesium chloride.
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
The present invention is Claim a positive control system (1) for container closure integrity (CCI) testing comprising a container and an adapter. The container (3) has a hollow interior (31), an opening (35) and an edge (331) surrounding the opening (35). The adapter (2) has a first coupling structure (21) configured to be connected to a flow reduction holder (4), and a second coupling structure (22). The second coupling structure (22) of the adapter (2) is vacuum tightly glued to the edge (331) of the container (3). The adapter (2) is configured such that the interior (31) of the container (3) is accessible from the first coupling structure (21).
G01M 3/32 - Investigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for containers, e.g. radiators
G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
25.
NOVEL PHAGOCYTOSIS ASSAY COMBINING A SYNTHETIC CELL DEATH SWITCH AND A PHAGOCYTOSIS REPORTER SYSTEM
The present invention relates to a recombinant expression vector encoding an inducible cell death switch, a pH-stable fluorophore and a pH-sensitive fluorophore. Moreover, the invention relates to cells comprising said recombinant expression vector as well as their use in an in vitro phagocytosis assay.
The invention related to a multidimensional LC system for analysing antibodies. The system provides multiple different measurement samples from a single sample, for example, the system may provide a native antibody sample for measurement, a reduced antibody sample for measurement and digested sample for peptide mapping from a single sample. The system has a fractionation module, a reduction module, a digestion module, a separation module and at least a first and a second splitter for splitting the flow.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Prediction of pharmacokinetic properties of chemical compounds A computer-implemented method of generating a machine-learning model configured to predict the value of one or more pharmacokinetic parameters of a pharmaceutical compound having a chemical structure comprises: receiving training data comprising a plurality of records, each record comprising: data encoding the chemical structure of a pharmaceutical compound; and the values of one or more pharmacokinetic parameters obtained from measurements taken from a human or animal subject after administration of the compound to the human or animal subject; and training the machine-learning model using the training data. Computer-implemented methods of utilizing the generated machine-learning model, particularly in a drug design context, are also provided.
The present invention relates to double-stranded RNA molecules conjugated to at least one conjugate moiety for topical administration to the eye, and pharmaceutical compositions thereof. The double-stranded RNA molecules are complementary, such as fully complementary, to targets expressed in the eye, and are capable of inhibiting expression of targets expressed in the eye. The double-stranded RNA molecules can be used in the treatment of conditions and diseases of the eye.
The present invention is directed to a packaging member (1) for a photosensitive drug substance being made of a substantially stiff sheet-like material which defines an outer packaging surface (20) and an inner packaging surface (30). The packaging member (10) comprises a front wall member (1), a rear wall member (2) and at least four side wall members (3, 4, 5, 6). The inner packaging surface (30) of at least one of the front wall member (1), the rear wall member (1) and/or the at least four side wall members (3, 4, 5, 6) comprises a colour being adapted to provide for a light absorption of at least about 50 %.
B65D 5/02 - Rigid or semi-rigid containers of polygonal cross-section, e.g. boxes, cartons or trays, formed by folding or erecting one or more blanks made of paper by folding or erecting a single blank to form a tubular body with or without subsequent folding operations, or the addition of separate elements, to close the ends of the body
B65D 81/30 - Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants by excluding light or other outside radiation
B65D 5/50 - Internal supporting or protecting elements for contents
31.
INSPECTION SYSTEM AND METHOD FOR A CLOSED MEDICAL CONTAINER
An inspection system (1.3) is operative to inspect a medical container containing a liquid. The inspection system (1.3) comprises an actuator (1.6) operative to displace a light source and/or detector of an optical system (1.5) relative to a sample holder (1.4) during data acquisition. Acquired data are analyzed to detect and/or determine characteristics of a particle in the medical container.
A computer-implemented method is provided for generating a trained TTS-GAN which may be used to generate synthetic longitudinal data for use in survival analysis, a clinical trial or clinical research. The TTS-GAN is configured to generate synthetic time-series data based on synthetic context data generated using a machine-learning model by virtue of being trained using training data comprising real context data and added noise data. A technique for executing survival analysis is also provided, which relies on the synthetic longitudinal data.
The present disclosure relates to the fields of molecular biology, more specifically antigen-binding molecule technology. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunotherapy.
-tert-tert-butyl-3-[(1-methyltetrazol-5- yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol for use in the treatment of diabetic retinopathy, and its methods of treatment thereof.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to novel antibodies which bind to human CB2. Further, the invention relates to a method of detecting changes in cell surface CB2 expression by flow cytometry in response to the treatment with a CB2 agonist. The method allows to assess and monitor target engagement of CB2 agonists thus supporting pre-clinical and clinical development of CB2 agonists.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described are antisense oligonucleotides comprising one or more α-L-threofuranosyl (TNA) nucleosides linked to an adjacent nucleoside via a phosphodiester (PO) internucleoside linkage, as well as methods to modulate the properties of antisense oligonucleotides by the introduction of such TNA nucleosides. These are particularly applicable to antisense gapmer oligonucleotides.
The present disclosure is directed to compositions and kits for PCR amplification. The present disclosure is also directed to methods of amplifying nucleic acid molecules to improve upon uniformity of coverage and/or to reduce GC bias during downstream sequencing operations.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Provided herein are compounds of Formula (I):
Provided herein are compounds of Formula (I):
and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Methods for the rapid detection of the presence or absence of Monkeypox Virus (MPXV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the MPXV F3L gene and the MPXV B21R gene, along with kits are provided that are designed for the detection of MPXV.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R411 are as defined above, composition including the compounds and methods of using the compounds.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Methods for quantifying amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models. The one or more machine-learning models are trained to generate a segmentation map based on the set of one or more brain-scan images, the segmentation map including a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map. The one or more machine-learning models are further trained to generate a classification score based on the segmentation map. The method thus includes detecting ARIA in the brain of the patient based on the classification score.
Methods for segmenting and detecting amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models trained to generate a segmentation map based on the set of one or more brain-scan images. The segmentation map includes a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map, in which at least one of the plurality of pixel-wise class labels includes an indication of ARIA in the brain of the patient. The method further includes outputting a quantification of ARIA in the brain of the patient based at least in part on the segmentation map.
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 293/10 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
47.
CONTAINER CLOSURE INTEGRITY TESTING METHOD AND SYSTEM
A container closure integrity (CCI) testing method for testing tightness of a stopper closure of a syringe (7), wherein the syringe has a syringe body (71) with a longitudinal axis, a hollow interior extending between an open first axial end and a second axial end with an orifice (712), and an elastic stopper (73) provided through the open first axial end into the hollow interior such that a chamber (74) is formed between the stopper (73) and the second axial end, comprises: providing the syringe (7) in a gas environment comprising a detection gas; moving the stopper (73) inside the hollow interior of the syringe body (71); and sensing for detection gas exiting the chamber (74) of the syringe (7) while moving the stopper (73) inside the hollow interior of the syringe body (71).
G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
The present invention provides a method comprising the steps of a) providing a nucleic acid comprising 5fC, 5hmC, or 5caC, b) providing one reactant comprising two reactive groups wherein the first reactive group is capable of reacting with the formyl hydroxymethyl or carboxyl group, and the second reactive group is a nucleophilic group, c) reacting said first reactive group with the formyl, hydroxymethyl or carboxyl group thereby resulting in a modified 5fC, 5hmC, or 5caC, d) reacting said second reactive group with the C6 position of said modified 5fC, 5hmC, or 5caC, thereby obtaining a bicyclic or tricyclic molecule comprising a 5,6-di-hydro Cytosine entity, and e) deaminating said 5,6-di-hydro Cytosine entity to a 5,6 di-hydro-Uracil entity.
The present invention relates to the prevention or mitigation of adverse effects related to gene therapy, such as the formation of anti-drug antibodies. Specifically, the invention relates to the prevention or mitigation of such side effects using a tyrosine kinase inhibitor such as dasatinib.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
51.
PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE
The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof. The invention further relates to certain synthetic intermediates that are useful for the novel process according to the invention. The process according to the invention is particularly suitable for large-scale manufacturing of the compound of formula (I) under GMP conditions.
C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein Y, R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the componds and methods of using the compounds.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the componds and methods of using the compounds.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
56.
METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FACTOR X
An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
The present invention relates to compounds of formula (I), wherein A1to A7and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
61.
MACHINE LEARNING ENABLED LOCALIZATION OF FOVEAL CENTER IN SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY VOLUME SCANS
A method and system for localizing a foveal center of a retina. An optical coherence tomography (OCT) volume for a retina of a subject is received. The OCT volume includes a plurality of OCT B-scans of the retina. A three-dimensional image input is generated for a model using the OCT volume. The model includes a three-dimensional convolutional neural network. The model is used to generate a foveal center position that includes three-dimensional coordinates for a foveal center of the retina based on the three-dimensional image input. The foveal center position may be used to generate an output that can be used in screening for retinal disease, diagnosing retinal disease, predicting treatment response, and/or managing retinal disease treatment.
The present disclosure relates generally to machine learning. More particularly, the present disclosure relates to federated learning. Moreover, the present invention relates to a system for federated learning, a computer program and a computer-readable medium.
The present invention relates to a method (200) of continuously in vivo detecting at least one analyte in a bodily fluid over a time span, an analyte sensor system (100) for in vivo continuously detecting at least one analyte in a bodily fluid over a measurement time span, a computer program and a computer-readable storage medium. The method (200) makes use of at least one analyte sensor (102) comprising at least one working electrode (104), configured for performing at least one electrochemical detection reaction with the analyte, and at least one further electrode (106), the further electrode (106) comprising at least one redox material composition, the redox material composition comprising silver and silver chloride, the method (200) comprising the following steps: monitoring at least one standard sensor signal (132) derived by using the analyte sensor (102) in a standard operation mode, comparing the standard sensor signal (132) with at least one threshold, thereby determining if a change of an operation mode of the analyte sensor (102) from the standard operation mode into an economy operation mode is required.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1495 - Calibrating or testing in vivo probes
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5and R6 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A biomedical knowledge graph system, the system including a computer database of records, the records comprising nodes of biomedical entities and connections between the entities representing biomedical relationships. One or more processors are programmed and configured to extract data from a plurality of data sources, determine biomedical entities and relationships between the entities based on analyzing the data, wherein analyzing the data comprises searching for predetermined identifiers or patterns in the data. Based on the determined biomedical entities, assigning each biomedical entity to a cluster of biomedical entity types. The one or more processors are configured to identify a context for each of the identified biomedical entities based on the assigned cluster and based on elements of the expression of the biomedical data within which the entity is expressed. Based on the identified context and type of the biomedical entity, incorporating records of nodes and connections between nodes into the knowledge graph, the nodes representing biomedical entities and the connections representing biomedical relationships between the entities structured according to the predefined schema.
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5and R6 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The invention provides a method of determining whether a subject has a neurological dysfunction associated with a signal in a particular electroencephalogram (EEG) or magnetoencephalogram (MEG) frequency range, the method comprising: obtaining an EEG power spectrum from the subject; and obtaining a metric quantifying the power in the power spectrum in the particular frequency range, wherein the metric summarises the power in said frequency range corrected using an estimate of the power in said frequency range that is attributable to background signal that is specific to said frequency range, wherein the metric is indicative of the presence and/or severity and/or direction of a neurological dysfunction. Related methods and devices are also described.
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/16 - Devices for psychotechnics; Testing reaction times
The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
71.
NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES
The invention relates to novel compounds having the general formula (I) wherein R1, R2, X1, X2, X3 and W are as described herein, composition including the compounds and methods of using the compounds.
C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to compounds of formula (I), wherein R1to R7, A1and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
The invention relates to novel compounds having the general formula (I) wherein R4, R512311 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Herein is reported a polypeptide-linker-nucleic acid conjugate, wherein the linker comprises a 3-amino propanamide unit, a 2,6-diamino hexanoic acid amide unit, and a 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, wherein the polypeptide comprises a C-terminal lysine residue, and wherein the nucleic acid comprises an oxygen linked to a phosphorous atom of the oxidation state V at the 5' or 3' terminus, wherein the 3-amino group of the 3-amino propanamide unit and the carboxy function of the lysine residue of the polypeptide are linked by/form an amide bond, the carboxy function of the 3-amino propanamide unit and the alpha amino group of the 2,6-diamino hexanoic acid amide unit are linked by/form an amide bond, the 6-amino group of the 2,6-diamino hexanoic acid amide unit is a nitrogen of the 1,2,3-triazole element of the 1,4,5,5a,6,6a,7,8- octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, and the oxygen linked to the phosphorous atom of the nucleic acid is covalently linked to the cyclopropane element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3- triazole unit.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C12P 13/00 - Preparation of nitrogen-containing organic compounds
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4 and W are as described herein, composition including the compounds and methods of using the compounds.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
76.
LEUKOTRIENE A4 HYDROLASE (LTA4H) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Meteorin-like protein (METRNL) in a sample of the subject.
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention relates to oligonucleotides for editing a target nucleic acid, as well as conjugates, salts and pharmaceutical compositions thereof. The invention also relates to uses of such oligonucleotides, conjugates, salts and pharmaceutical compositions in methods for editing target nucleic acids and in medical uses and methods of treatment of disease.
The invention relates to novel compounds having the general formula I wherein R1, R21233 and W are as described herein, composition including the compounds and methods of using the compounds.
C07D 221/04 - Ortho- or peri-condensed ring systems
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
82.
NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES
The invention relates to novel compounds having the general formula I wherein R1, R21233 and W are as described herein, composition including the compounds and methods of using the compounds.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
83.
RATIO BETWEEN LTA4H AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total LTA4H in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentration determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total FGFBP1 in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentrations determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
The disclosure refers to a method of operating a laboratory sample distribution system having a plurality of carriers (4) configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) assigned to the laboratory devices (3) and providing support to the plurality of carriers (4); and a driving device (13) configured to move, in response to driving control signals, the plurality of carriers (4) between plane positions (5) provided on the transport plane (1). The method comprises: prior to moving the carriers (4) on the transport plane (1), pre-determining off-line routes (6) on the transport plane (1) by one or more processors of a data processing device, the pre-determining comprising: determining a model representing the transport plane (1) with plane locations (5') and location-to-location movements between plane locations (5') associated to the plurality of carriers (4) calculating an optimized set of off-line routes between pairs of plane locations from the plurality of plane locations (5') using the model, the calculating comprising solving an optimization problem in which routes between the pairs of plane locations are simultaneously optimized; and providing the optimized set of off-line routes as off-line routes (6) on the transport plane (1); and controlling the driving device (13) such that the carriers (4) are moved along the pre-determined off-line routes (6) on the transport plane (1). Furthermore, a laboratory sample distribution system, and a laboratory automation system are provided.
G06Q 10/0835 - Relationships between shipper or supplier and carriers
B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
86.
METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM
The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method com- prises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route seg- ment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential dead- lock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individ- ual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
G06Q 10/0835 - Relationships between shipper or supplier and carriers
B65G 54/02 - Non-mechanical conveyors not otherwise provided for electrostatic, electric, or magnetic
The present invention relates to compounds of formula (I), wherein R1to R3, M, A, Y and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
Herein is reported a method for lysing recombinant AAV particle producing mammalian cells comprising the step of bringing a mammalian cell cultivation broth in contact with an alkyl polyglucoside detergent, preferably Triton CG 110, and thereby lysing recombinant AAV particle producing mammalian cells and releasing the produced recombinant AAV particles, wherein the mammalian cell cultivation broth comprises cultivated recombinant AAV particle producing mammalian cells and the cultivation medium used for the cultivation of said recombinant AAV particle producing mammalian cells (spent medium).
The present invention relates to a mutant ketoreductase, a nucleic acid encoding the mutant ketoreductase, a vector comprising the nucleic acid, a method for the enzymatic reduction of a prochiral ketone and the formation of a chiral alcohol with the mutant ketoreductase, the use of the mutant ketoreductase for the preparation of chiral alcohols as well as the use of the method for the preparation of pharmaceutically active morpholine compounds.
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a medical infusion device comprising a reservoir for holding a liquid medicament, a cannula assembly, a fluid line, a drive mechanism, a dispensing member for dispensing medicament from reservoir through the fluid line and the cannula assembly, and a leakage determining module. For a more convenient determination of leakage of liquid medicament, the leakage determining module comprises an electronic probe that is configured for receiving odor molecules and/or flavor molecules of the liquid medicament and in that the leakage determining module further comprises evaluation electronics that is configured to determine presence of odor and/or flavor of the liquid medicament based on readings of the at least one electronic probe.
The present invention relates to compounds of formula (I), wherein R1to R3 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
93.
A METHOD FOR QUALITY CHECK OF AT LEAST ONE LC-MS MEASUREMENT
A method for quality check of at least one Liquid Chromatography-Mass Spectrometry (LC-MS) measurement on a sample comprising an analyte of interest and a defined amount of at least one internal standard is proposed. The method comprises the following steps a) (120) determining an information (peakAreaaqn) about an analyte signal and an information (peakAreatqn) about an internal standard signal of the LC-MS measurement; b) (122) determining at least one monitoring parameter by using the information about the analyte signal and the information about the internal standard signal by using at least one processing device (114), wherein the monitoring parameter comprises a minimal limit for the internal standard signal for said analyte signal of said sample; c) (124) comparing the information about the internal standard signal to the monitoring parameter by using the processing device (114), wherein the LC-MS measurement is flagged by using the processing device (114) as to fulfil the quality check in case the information about the internal standard signal is greater or equal to the monitoring parameter or otherwise as failed.
The present disclosure provides a method for enrichment of at least one target nucleic acid in a library of nucleic acids. This present disclosure is also directed to a faster and easier method of target capture using primer extension reactions that can improve ease of use, turnaround time, and variant allele specificity by designing target enrichment primers to specifically enrich library fragments based on the relative location of the variant base(s) in the primer, the utilization of polymerases with better priming specificity, designing the variant bases in the capture primer, designing the variant bases in the release primer, and/or designing variant specific primers to the both the plus and minus strands of the target library fragment.
A door mechanism device (110) for a door (100) for a transport apparatus (500) for trans- porting a sample container carrier is disclosed. The door mechanism device (110) comprises at least a first fixation bracket (112) configured for mounting the door mechanism device (110) to a frame of the transport apparatus, at least a first upper lever (114), at least a first lower lever (116), at least a first door mount (120) configured to be mounted to a cover (102) of a door (100) of the transport apparatus. The first upper lever (114) and the first lower lever (116) are rotatably mounted to the first fixation bracket (112) and the first door mount (120). The first upper lever (114) and the first lower lever (116) are rotatable around lever axes (122) such that the first door mount (120) is movable between a first position and a second position with the first door mount (120) substantially maintaining its orientation within a plane perpendicular to the lever axes (122). Further, a door (100) for a transport apparatus for transporting a sample container carrier and a transport apparatus (500) for transporting a sample container carrier are disclosed.
The present invention relates to compounds of formula (I), wherein R1to R6, A1and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds as KRAS inhibitors.
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
97.
PREDICTION OF THE PRESENCE OF A HISTOPATHOLOGICAL ABNORMALITY
The present invention is directed towards the application of toxicogenomic methods to the detection and/or prediction of histopathological abnormalities in human or animal subjects based on clinical pathology data. It has been observed that reliable results may be obtained in the absence of any image data. A computer-implemented method of predicting the presence of a histopathological abnormality in an organ of a human or animal subject based on clinical pathology data comprises: receiving clinical pathology data obtained from the human or animal subject; applying an analytical model to the clinical pathology data, the analytical model configured to output a result indicative of the likelihood of the presence of a histopathological abnormality in the organ of the human or animal subject; and outputting the result.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
98.
MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER
The present invention relates to compounds of formula (I), wherein R1to R7, A1and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 498/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
C07D 515/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains three hetero rings
A method may include applying a protein sequence computation model to generate, based on an input protein sequence, a plurality of proposed protein sequences. A set of possible amino acid residues for each position in at least a portion of an output protein sequence may be identified based on the plurality of proposed protein sequences. A first protein structure having the output protein sequence may be generated by applying a protein structure computation model to select, for each position in at least the portion of the output protein sequence, an amino acid residue from a corresponding set of possible amino acid residues. The protein structure computation model may further determine the conformation of the amino acid residues selected for inclusion in the output protein sequence. In some cases, the first protein structure may be grafted onto a second protein structure to form a third protein structure.